pioglitazone has been researched along with Infarction, Middle Cerebral Artery in 13 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent researches highlighted the protective potential of pioglitazone, a PPAR-γ agonist, in the progression of cerebral ischemia-reperfusion injury." | 3.88 | Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ. ( Guo, Q; Pan, Y; Wang, E; Wang, N; Xia, P; Ye, Z; Zhang, F, 2018) |
| "These mice received a middle cerebral artery occlusion and reperfusion injury, and they were evaluated for the infarct volume and by immunohistochemistry and western blotting analysis at several time points after ischemia." | 1.62 | Pioglitazone Prevents Hemorrhagic Infarction After Transient Focal Ischemia in Type 2 Diabetes. ( Arai, H; Hasegawa, H; Hattori, N; Mitome-Mishima, Y; Miyamoto, N; Oishi, H; Tanaka, R; Urabe, T; Yatomi, K, 2021) |
| "Hyperglycemia was induced by streptozotocin treatment." | 1.42 | Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. ( Gliem, M; Hartung, HP; Jander, S; Klotz, L; van Rooijen, N, 2015) |
| "Permanent middle cerebral artery occlusion (pMCAO) model was induced by using an intraluminal filament technique in rats." | 1.37 | Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway. ( Hong, LZ; Liu, CF; Liu, J; Qin, AP; Qin, ZH; Wei, C; Xu, M; Zhang, HL; Zhao, XY, 2011) |
| "Pioglitazone or vehicle was infused intracerebroventricularly over a 5-day period before, during and 24 or 48 h after middle cerebral artery occlusion." | 1.36 | Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Stöck, I; Zhao, Y, 2010) |
| " Translation of these findings into clinical therapy will require careful assessment of dosing paradigms and effective time windows for treatment." | 1.36 | Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. ( Blankenship, DA; Gamboa, J; Hilow, E; Karl, M; Landreth, GE; Niemi, JP; Sundararajan, S, 2010) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| "Pioglitazone or vehicle were i." | 1.33 | The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Zhao, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, H | 1 |
| Yatomi, K | 1 |
| Mitome-Mishima, Y | 1 |
| Miyamoto, N | 1 |
| Tanaka, R | 1 |
| Oishi, H | 1 |
| Arai, H | 1 |
| Hattori, N | 1 |
| Urabe, T | 1 |
| Xia, P | 1 |
| Pan, Y | 1 |
| Zhang, F | 1 |
| Wang, N | 1 |
| Wang, E | 1 |
| Guo, Q | 1 |
| Ye, Z | 1 |
| Gliem, M | 1 |
| Klotz, L | 1 |
| van Rooijen, N | 1 |
| Hartung, HP | 1 |
| Jander, S | 1 |
| Patzer, A | 2 |
| Zhao, Y | 4 |
| Stöck, I | 2 |
| Gohlke, P | 4 |
| Herdegen, T | 3 |
| Culman, J | 4 |
| Ji, S | 1 |
| Kronenberg, G | 1 |
| Balkaya, M | 1 |
| Färber, K | 1 |
| Gertz, K | 1 |
| Kettenmann, H | 1 |
| Endres, M | 1 |
| Glatz, T | 1 |
| Nguyen-Ngoc, M | 1 |
| Gamboa, J | 1 |
| Blankenship, DA | 1 |
| Niemi, JP | 1 |
| Landreth, GE | 2 |
| Karl, M | 2 |
| Hilow, E | 2 |
| Sundararajan, S | 3 |
| Zhang, HL | 1 |
| Xu, M | 1 |
| Wei, C | 1 |
| Qin, AP | 1 |
| Liu, CF | 1 |
| Hong, LZ | 1 |
| Zhao, XY | 1 |
| Liu, J | 1 |
| Qin, ZH | 1 |
| Zuhayra, M | 1 |
| von Forstner, C | 1 |
| Henze, E | 1 |
| Lützen, U | 1 |
| Blankenship, D | 1 |
| Niemi, J | 1 |
| Gamboa, JL | 1 |
| Victor, NA | 1 |
| Wanderi, EW | 1 |
| Lust, WD | 1 |
| Shimazu, T | 1 |
| Inoue, I | 1 |
| Araki, N | 1 |
| Asano, Y | 1 |
| Sawada, M | 1 |
| Furuya, D | 1 |
| Nagoya, H | 1 |
| Greenberg, JH | 1 |
13 other studies available for pioglitazone and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Pioglitazone Prevents Hemorrhagic Infarction After Transient Focal Ischemia in Type 2 Diabetes.
Topics: Adiponectin; Animals; Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Infarction, Middle Cerebral | 2021 |
Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ.
Topics: Animals; Astrocytes; Cells, Cultured; Glucose; HMGB1 Protein; Infarction, Middle Cerebral Artery; Ma | 2018 |
Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke.
Topics: Animals; Anticoagulants; Cell Polarity; Cerebral Hemorrhage; Diabetes Mellitus, Experimental; Diseas | 2015 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Bromodeoxyuridine; Calcium-Binding Proteins; Cell | 2009 |
Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.
Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Infarction, Middle Cerebral Artery; Interleukin | 2010 |
Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.
Topics: Animals; Behavior, Animal; Blood Pressure; Brain; Brain Ischemia; Cell Adhesion Molecules; Disease M | 2010 |
Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Immunohistochemistry; Infarction, Middle | 2011 |
Activation of cerebral peroxisome proliferator-activated receptors γ (PPARγ) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat.
Topics: Animals; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Neurons; Neuroprotect | 2011 |
Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats.
Topics: Administration, Oral; Animals; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Hypoglyc | 2011 |
Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.
Topics: Animals; Blood Glucose; Brain Chemistry; Cell Count; Cerebrovascular Circulation; Chromans; Dose-Res | 2005 |
A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia.
Topics: Animals; Blood-Brain Barrier; Blotting, Western; Brain; Brain Ischemia; Cerebrovascular Circulation; | 2005 |
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalit | 2005 |